title: Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent.
abstract: OBJECTIVE
  To identify risk factors for clinical-driven target lesion revascularisation (TLR) in patients treated with sirolimus-eluting (Cypher) or paclitaxel-eluting (Taxus) stents in a real-world scenario.
  
  
  METHODS
  From 1 January 2003 to 18 May 2005, all patients treated with a Cypher or Taxus stent were consecutively registered and followed for 9 months. Re-intervention was driven by clinical symptoms.
  
  
  METHODS
  Western Denmark Heart Registry.
  
  
  METHODS
  4432 patients with 6102 lesions treated with a Cypher (n = 3791 lesions) or Taxus (n = 2311 lesions) stent.
  
  
  METHODS
  Percutaneous coronary intervention.
  
  
  METHODS
  TLR, defined as either new percutaneous coronary intervention or coronary artery bypass graft operation of the target lesion, within 9 months from the index procedure.
  
  
  RESULTS
  TLR within 9 months was performed in 2.5% of lesions treated with the Cypher stent and in 3.3% of lesions treated with the Taxus stent (OR 1.36, 95% CI 1.00 to 1.84). After adjustment by multivariate logistic regression, Taxus stent implantation was an independent predictor of TLR (OR 1.43, 95% CI 1.05 to 1.95). Implantation of >1 stent per lesion (OR 1.62, 95% CI 1.13 to 2.33) and reference diameter <2.8 mm (OR 1.42, 95% CI 1.00 to 2.02) were also identified as independent predictors of TLR.
  
  
  CONCLUSIONS
  These data from the registry reflect a real-world clinical scenario with operator-driven use of drug-eluting stents and symptom-driven re-intervention. In this setting, use of the Taxus stent, implantation of multiple stents per lesion and stent implantation in small vessels were independent predictors of TLR.
authors.affiliation: Department of Cardiology, Skejby Sygehus, Aarhus University Hospital, Aarhus, Denmark. michael.maeng@ki.au.dk
authors.forename: Michael
authors.initials: M
authors.lastname: Maeng
authors.forename: Lisette
authors.initials: L
authors.lastname: Okkels Jensen
authors.forename: Klaus
authors.initials: K
authors.lastname: Rasmussen
authors.forename: Jens
authors.initials: J
authors.lastname: Flensted Lassen
authors.forename: Lars
authors.initials: L
authors.lastname: Romer Krusell
authors.forename: Per
authors.initials: P
authors.lastname: Thayssen
authors.forename: Leif
authors.initials: L
authors.lastname: Thuesen
mesh_terms: D000704:Analysis of Variance; D015906:Angioplasty, Balloon, Coronary; D023903:Coronary Restenosis / Q000453:epidemiology / Q000628:therapy*; D023921:Coronary Stenosis / Q000628:therapy*; D003718:Denmark; D016503:Drug Delivery Systems; D004867:Equipment Design; D006801:Humans; D016015:Logistic Models; D017239:Paclitaxel / Q000008:administration & dosage*; D012042:Registries; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D015607:Stents; D016896:Treatment Outcome
chemical_list: D017239:Paclitaxel; D020123:Sirolimus